Publication & Citation Trends
Most Cited Works
Publications
141 total
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer PDF
Cited by 226
OpenAlex
Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid Tumors PDF
Cited by 694
OpenAlex
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Cited by 123
OpenAlex
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies PDF
Cited by 411
OpenAlex
The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
Cited by 146
OpenAlex
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development PDF
Cited by 293
OpenAlex
Research Topics
Cancer-related Molecular Pathways
(49)
Monoclonal and Polyclonal Antibodies Research
(31)
CAR-T cell therapy research
(27)
Lung Cancer Research Studies
(21)
Cancer, Hypoxia, and Metabolism
(20)
Frequent Co-Authors
Affiliations
Amgen (United States)
University of California, Los Angeles
Avera Health
University of Warwick
Electronic Sensor Technology (United States)